Danaher (NYSE:DHR – Get Free Report) had its price objective boosted by analysts at Bank of America from $270.00 to $275.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the conglomerate’s stock. Bank of America‘s price target points to a potential upside of 1.82% from the stock’s previous close.
Other analysts have also recently issued reports about the stock. Jefferies Financial Group started coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. HSBC raised Danaher from a “hold” rating to a “buy” rating and raised their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. TD Cowen boosted their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Evercore ISI lowered their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, Citigroup upped their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $276.88.
View Our Latest Analysis on DHR
Danaher Trading Up 1.6 %
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 10.90% and a net margin of 16.94%. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the company posted $2.05 EPS. The firm’s revenue was down 2.9% on a year-over-year basis. Analysts expect that Danaher will post 7.62 EPS for the current fiscal year.
Insider Buying and Selling at Danaher
In other news, CEO Rainer Blair sold 19,085 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total value of $4,866,675.00. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $29,578,725. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Rainer Blair sold 19,085 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total value of $4,866,675.00. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $29,578,725. The disclosure for this sale can be found here. Over the last three months, insiders sold 75,175 shares of company stock valued at $19,161,154. 11.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in DHR. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher during the 4th quarter worth approximately $25,000. Tsfg LLC grew its position in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Danaher in the 4th quarter valued at about $29,000. Finally, Redmont Wealth Advisors LLC bought a new position in Danaher during the 1st quarter worth approximately $30,000. 79.05% of the stock is owned by institutional investors.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Investing in Construction Stocks
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Earnings Per Share Calculator: How to Calculate EPS
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.